Clean Science and Technology (CLEAN) investor relations material

Executive summary

• Achieved highest-ever consolidated sales in Q1 FY27, with revenue between INR 264 crore and INR 268 crore, reflecting 7–8% sequential and 10–11% YoY growth, driven by HALS business scale-up and improved product mix despite global headwinds.

• Continued diversification of product portfolio, with HALS now constituting 22% of sales and exports accounting for nearly 50% of HALS revenue.

• Strategic investments in capex and global expansion, including a new Netherlands subsidiary and advanced manufacturing facilities.

• Board approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.

• Appointment of Mr. Krishnakumar Satyanarain Saboo as Additional Director and recommendation for Whole-time Director for five years.

Financial highlights

• Consolidated revenue for Q1 FY27 was ₹2,684.32 million (INR 268 crore), up from ₹2,428.69 million YoY; standalone revenue at ₹2,071.04 million (INR 207 crore).

• EBITDA stood at INR 96 crore (36.5–37% margin); PAT at INR 73 crore (27.8–28% margin).

• Standalone EBITDA margin at 42.7–43%, PAT margin at 36%.

• Standalone export/domestic mix at 35%/65%; 61% of consolidated revenues from exports.

• Basic and diluted EPS for Q1 FY27 stood at ₹6.90 (consolidated and standalone).

Outlook and guidance

• HALS revenue for FY27 targeted at INR 250–300 crore, expected to be 30–35% of total revenue.

• Geneus Chem partnership projected to add INR 300–350 crore cumulative revenue over 3–4 years.

• Performance Chemical 2 plant to be commercialized by Q3 FY27, with major revenue contribution from Q1 next year.

• Strategic collaboration with a Swiss technology partner to accelerate advanced HALS development.

• Upon exercise of warrants, subsidiary will acquire 25% of Geneus Chem AG.